Durect Corp (DRRX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire CUPERTINO...

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update PR...

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase...

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR...

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business...

Form 8-K - Current report

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR...